Optiscan (ASX: OIL) has been included in an article published in both The Australian and Stockhead highlighting local health and medtech companies embracing opportunities to manufacture products in Australia.

The piece underscores the innovative nature of Optiscan's telepathology platform, which allows for real-time, non-invasive imaging at the single-cell level.

"OIL, is a global leader in developing, manufacturing, and commercialising confocal endomicroscopy imaging technologies for medical, translational, and pre-clinical applications. The company's technology, known as optical biopsy, generates real-time microscopic images, potentially eliminating the need for physical biopsies."

Read the full articles here:

The Australian

Stockhead